23andMe Investor Presentation Deck
23ME'610 Targeting CD200R1: A Genetically-Validated
Approach to Anti-Cancer Therapy
CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway
23ME-00610 is a high-affinity, first-in-class, anti-CD200R1 antibody with immune-activating properties,
including:
Prevention of CD200-mediated suppression of chronically stimulated T cells
Enhancement of cytokine secretion from peripheral blood mononuclear cells (PBMCs) isolated from cancer
patients
Augmentation of PBMC-mediated tumor cell killing
CD200R1 expression was observed on tumor infiltrating lymphocytes from The Cancer Genome Atlas,
suggesting that this pathway contributes to an immunosuppressive tumor microenvironment.
CD200R1 was also expressed in immune checkpoint inhibitor non-responders, indicating that inhibition of the
CD200R1 immune checkpoint has the potential to address resistance to anti-PD-1 and anti-CTLA4 therapies
The Phase 1 dose escalation study of 23ME'610 in patients with advanced solid malignancies was initiated in
January 2022View entire presentation